The addition of FES-PET to NCCN guidelines is more than a clinical endorsement; it's a critical lever for overcoming access barriers. This inclusion signals to insurance payers that the imaging should be covered and prompts unfamiliar oncologists to learn about and adopt the technology, accelerating its transition into standard care.
A Mayo Clinic study found that FES-PET scan results led to a change in medical therapy, surgery, or radiation for 37% of patients with invasive lobular carcinoma. This demonstrates the technology's immediate, significant impact on clinical decision-making, going beyond mere diagnostic clarification to actively reshape patient care pathways.
Current imaging often underestimates axillary lymph node involvement in lobular cancer, making surgeons hesitant to de-escalate procedures. By providing a more accurate assessment, FES-PET could give clinicians the confidence to safely perform less extensive axillary surgeries, aligning with the modern goal of avoiding patient overtreatment.
FES-PET's ability to visualize estrogen receptor activity may solve a critical dilemma: identifying which patients have become endocrine-resistant. A lack of signal on an FES-PET scan could indicate that a patient won't benefit from more endocrine-based treatments, enabling a faster, more effective pivot to cytotoxic therapies.